Xinteza API

Company Overview

Snapshot

Founded in March 2019 by Alon Gal, Ron Klein, and Zohar Koren, Xinteza API operates with 1–10 employees. The company has secured one funding round and holds patents related to its biosynthesis and bioextraction technologies. In February 2023, Xinteza API announced a breakthrough in developing true water-soluble cannabinoids through glycosylated cannabinoid genes and enzymes, a discovery made in collaboration with the Weizmann Institute of Science.

Business overview

Xinteza API is a biotechnology company focused on developing advanced proprietary biosynthesis and bioextraction technologies for producing cannabinoid-based active pharmaceutical ingredients (APIs). The company's core technology involves the research and discovery of novel genes and genetic pathways for the biosynthesis of cannabinoids and psychoactive ingredients, along with the development of their bioproduction methods. Xinteza API holds an exclusive license for cannabinoids and psychoactives from the Weizmann Institute and serves the pharmaceutical and food industries, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Medical Cannabis.

Strategic signal

In February 2023, Xinteza API announced a significant breakthrough with the discovery of glycosylated cannabinoid genes and enzymes, enabling the production of true water-soluble cannabinoids. This innovation eliminates the need for traditional liposomes or nanoparticles, offering a cleaner and more sustainable alternative to oil-based cannabinoid products. This development signals a potential for significant disruption in the beverage, cosmetics, and pharmaceutical industries by providing a more versatile and efficient form of cannabinoid integration, enhancing product development and market reach.

Company Intelligence Q&A

What was Xinteza API's key technological breakthrough announced in February 2023?

In February 2023, Xinteza API announced the discovery of glycosylated cannabinoid genes and enzymes, enabling the production of true water-soluble cannabinoids. This breakthrough, made by Prof. Asaph Aharoni at the Weizmann Institute of Science, eliminates the need for liposomes or other nanoparticles in cannabinoid products.

What was the significance of Xinteza API's enzyme discovery in September 2022?

In September 2022, Xinteza API introduced a novel catalytic enzyme, PT-X, designed to improve cannabinoid biosynthesis production systems. This enzyme offers enhanced catalytic activity and compatibility for integration into micro-organism-based industrial production, aiming to significantly improve the cost-to-efficacy ratio of cannabinoid biosynthesis.

What was the nature of IM Cannabis's investment in Xinteza API?

In January 2020, IM Cannabis Corp. announced an investment in Xinteza API's biosynthesis technology, acquiring 25% of Xinteza's outstanding common shares for up to $1.7 million. This investment aimed to support the development of low-cost, scalable methods for producing cannabinoid-based active pharmaceutical ingredients.

What is Xinteza API's relationship with the Weizmann Institute of Science?

Xinteza API operates in collaboration with the Weizmann Institute of Science and holds an exclusive license for cannabinoids and psychedelics from the institute. This partnership is central to their research and development efforts, including the discovery of novel genes and enzymes for cannabinoid biosynthesis.

What is Xinteza API's primary focus in product development?

Xinteza API is primarily focused on developing advanced proprietary biosynthesis and bioextraction technologies for the production of cannabinoid-based active pharmaceutical ingredients (APIs). Their work involves discovering new genes and genetic pathways for cannabinoids and psychoactive ingredients, targeting both the pharmaceutical and food industries.